$4.24
-0.26 (-5.78%)
Open$4.58
Previous Close$4.50
Day High$4.60
Day Low$4.15
52W High$7.75
52W Low$1.36
Volume—
Avg Volume213.3K
Market Cap282.39M
P/E Ratio—
EPS$-2.24
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+183.3% upside
Current
$4.24
$4.24
Target
$12.01
$12.01
$8.14
$12.01 avg
$13.09
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 368.79M | 346.38M | 334.67M |
| Net Income | 5.96M | 4.54M | 4.70M |
| Profit Margin | 1.6% | 1.3% | 1.4% |
| EBITDA | 7.81M | 7.32M | 6.13M |
| Free Cash Flow | 4.41M | 4.25M | 6.96M |
| Rev Growth | +17.9% | -7.3% | +7.0% |
| Debt/Equity | 0.83 | 0.86 | 0.78 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |